Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies

Drugs of Today

Volumn 35, Issue 9, 1999, Pages 701-717

  Rabasseda, X ^a,b  

^a Medical Information Department   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA;

DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; PARKINSON DISEASE; REVIEW;

EID: 0032712818     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.9.553216     Document Type: Review

References (43)

1. Parkinson, J. An Essay on the Shaking Palsy. Sheerwood, Neely & Jones: London 1817.
2. Nutt, J.G. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Adv Neurol 1996, 69: 493-6.
3. Männisto, P.T. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994, 1 (3): 172-9.
4. Kaakkola, S., Gordin, A., Männisto, P.T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994, 25 (5): 813-24.
5. Schultz, E., Nissinen, E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 1989, 38 (22): 3953-6.
6. Männisto, P.T., Tuomainen, P., Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol 1992, 105 (3): 569-74.
7. Keränen, T., Gordin, A., Karlsson, M. et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994, 46 (2): 151-7.
8. Wikberg, T., Ottoila, P., Taskinen, J. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog. Eur J Drug Metab Pharmacokinet 1993, 18 (4): 359-67.
9. Wikberg, T., Vuorela, A., Ottoila, P., Taskinen, J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993, 21 (1): 81-92.
10. Nutt, J.G., Woodward, W.R., Beckner, R.M. et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994, 44 (5): 913-9.
11. Waldmeier, P.C., De, H.P., Maitre, L. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat. J Neural Transm Suppl 1990, 32: 381-6.
12. Zurcher, G., Colzi, A., Da, P.M. Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990, 32: 375-80.
13. Nissinen, E., Linden, I.B., Schultz, E., Pohto, P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmied Arch Pharmacol 1992, 346 (3): 262-6.
14. Guttman, M., Leger, G., Reches, A. et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993, 8 (3): 298-304.
15. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology 1994, 44 (7): 1292-7.
16. Smith, L.A., Gordin, A., Jenner, P., Marsden, C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 1997, 12 (6): 935-45.
17. Sundberg, S. et al. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993, 36: 451-6.
18. Keränen, T., Gordin, A., Harjola, V.P. et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993, 16 (2): 145-56.
19. Illi, A., Sundberg, S., Koulu, M., Scheinin, M., Heinavaara, S., Gordin, A. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994, 32 (11): 582-8.
20. Sundberg, S., Scheinin, M., Ojala-Karlsson, P., Akkila, J., Gordin, A. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur J Clin Pharmacol 1993, 44 (3): 287-90.
21. Ahtila, S., Kaakkola, S., Gordin, A. et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995, 18 (1): 46-57.
22. Ishikawa, T., Dhawan, V., Chaly, T. et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996, 16 (5): 854-63.
23. Ruottinen, H.M., Rinne, U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996, 19 (4): 283-96.
24. Illi, A., Sundberg, S., Ojala-Karlsson, P., Scheinin, M., Gordin, A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions. Eur J Clin Pharmacol 1996, 51 (3-4): 273-6.
25. Illi, A., Sundberg, S., Ojala-Karlsson, P., Scheinin, M., Gordin, A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996, 59 (4): 450-7.
26. Illi, A., Sundberg, S., Ojala-Karlsson, P., Korhonen, P., Scheinin, M., Gordin, A. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 1995, 58 (2): 221-7.
27. Myllylä, V.V., Sotaniemi, K.A., Illi, A., Suominen, K., Keränen, T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993, 45 (5): 419-23.
28. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995, 10 (2-3): 91-106.
29. 18F]fluorodopa (FDOPA) accumulation after entacapone administration. Neurology 1997, 48 (3): A186.
30. Ruottinen, H.M. et al. Prolonged FDOPA PET imaging after peripheral COMT inhibition. J Cereb Blood Flow Metab 1997, 17 (Suppl. 1): S737.
31. Kaakkola, S., Teravainen, H., Ahtila, S., Rita, H., Gordin, A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994, 44 (1): 77-80.
32. Kaakkola, S. et al. Entacapone in combination with standard or controlled-release levodopa/carbidopa: A clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995, 2: 341-7.
33. Ruottinen, H.M., Rinne, U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996, 19 (3): 222-33.
34. Ruottinen, H.M., Rinne, U.K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996, 60 (1): 36-40.
35. Merello, M., Lees, A.J., Webster, R., Bovingdon, M., Gordin, A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994, 57 (2): 186-9.
36. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997, 42 (5): 747-55.
37. Rinne, U.K., Larsen, J.P., Siden, A., Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998, 51 (5): 1309-14.
38. Keränen, T., Gordin, A., Koula, M. et al. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. J Neural Transm Gen Sect 1996, 103 (6): 729-36.
39. Ruottinen, H.M., Rinne, U.K. COMT inhibition in the treatment of Parkinson's disease. J Neurol 1998, 245 (11, Suppl. 3): 25-34.
40. Squires, R.F. Discovery of monoamine oxidase forms A and B. Vopr Med Khim 1997, 43 (6): 433-9.
41. Shin, J.C., Chen, K., Ridd, M.J. Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 1999, 22: 197-217.
42. Olanow, C.W. MAO-B inhibitors in Parkinson's disease. Adv Neurol 1993, 60: 666-71.
43. Youdim, M.B. Pharmacology of MAO B inhibitors: Mode of action of (-)-deprenyl in Parkinson's disease. J Neural Transm Suppl 1986, 22: 91-105.